Literature DB >> 19579641

Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH.

Hiroshi Iida1, Masahiko Inamori, Keiko Akimoto, Hironori Mawatari, Hiroki Endo, Yuichi Nozaki, Tomoyuki Akiyama, Tamon Ikeda, Yasunari Sakamoto, Koji Fujita, Kyoko Yoneda, Hirokazu Takahashi, Masato Yoneda, Ayumu Goto, Yasunobu Abe, Noritoshi Kobayashi, Hiroyuki Kirikoshi, Kensuke Kubota, Satoru Saito, Atsushi Nakajima.   

Abstract

BACKGROUND/AIMS: The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after single intravenous administrations of lansoprazole 30 mg and famotidine 20 mg.
METHODOLOGY: Twelve Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 4 hours after single intravenous administration of lansoprazole 30 mg or famotidine 20 mg.
RESULTS: The average pH during the 4-hour period after administration of famotidine was higher than after lansoprazole (median: 5.15 versus 3.55, respectively; p = 0.0376). During the 4-hour study period, famotidine 20 mg provided a longer duration of pH > 3, 3.5, 4, 5, 6 and 7, compared to lansoprazole 30 mg (median: 73.6% versus 57.0%; p = 0.0414, 66.8% versus 47.8%; p = 0.0281, 60.8% versus 38.8%; p = 0.0150, 55.7% versus 29.7%; p = 0.0281, 45.0% versus 23.1%; p = 0.0414 and 23.9% versus 3.65%; p = 0.0076).
CONCLUSIONS: In Helicobacter pylori-negative healthy male subjects, an intravenous dose of famotidine 20 mg more rapidly increases intragastric pH than lansoprazole 30 mg.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579641

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Early effects of oral administration of omeprazole and roxatidine on intragastric pH.

Authors:  Hiroshi Iida; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroki Endo; Kunihiro Hosono; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

2.  Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.

Authors:  Xian-Bao Zhan; Xiao-Rong Guo; Zhao-Shen Li; Yan-Fang Gong; Jun Gao; Zhuan Liao; Zhen Li; Shen Gao; Pei Liu
Journal:  Med Sci Monit       Date:  2012-02

3.  Effects of Histamine-2 Receptor Antagonists and Proton Pump Inhibitors on the Rate of Gastric Emptying: A Crossover Study Using a Continuous Real-Time C Breath Test (BreathID System).

Authors:  Takashi Nonaka; Takaomi Kessoku; Yuji Ogawa; Kento Imajyo; Shogo Yanagisawa; Tadahiko Shiba; Takashi Sakaguchi; Kazuhiro Atsukawa; Hisao Takahashi; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroshi Iida; Kunihiro Hosono; Hiroki Endo; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Yasunobu Abe; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Neurogastroenterol Motil       Date:  2011-07-13       Impact factor: 4.924

4.  PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.

Authors:  Chen Mo; Gang Sun; Yan-Zhi Wang; Ming-Liang Lu; Yun-Sheng Yang
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

5.  Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study.

Authors:  Kanji Ohkuma; Hiroshi Iida; Yumi Inoh; Kenji Kanoshima; Hidenori Ohkubo; Takashi Nonaka; Koji Fujita; Akihiko Kusakabe; Masahiko Inamori; Atsushi Nakajima
Journal:  J Clin Biochem Nutr       Date:  2018-05-09       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.